Redesigning the rules of compatibilityTM
We’re building a universal donor cell platform designed to enable scalable, immune-compatible, off-the-shelf allogeneic therapies for cell and tissue transplantation.
About us
Altera Biosciences is a preclinical-stage biotechnology company developing a universal donor cell platform to power the next generation of off-the-shelf allogeneic cell therapies.
Our mission is to remove the barriers of immunogenicity and donor-matching through cell engineering — making cell therapy more scalable, accessible, and impactful across the globe.
We’re driven by a belief that advanced therapies should be designed for everyone — not just a few. That’s why we’re focused on creating foundational technologies that unlock long-term, off-the-shelf solutions for diverse patient populations.
Why Universal Donor Cells matter
The success of both cell-based and organ transplantation is often limited by one critical factor: immune compatibility. Whether in advanced therapies or life-saving transplants, patients typically require cells or organs that are immunologically matched — a process that depends on scarce donor availability, individualized preparation, and lifelong immunosuppression.
These limitations result in morbidity and mortality as a consequence of delayed treatments, high costs, and restricted access — particularly in low-resource or time-sensitive settings.
Universal donor cells represent a potential paradigm shift: engineered to be immune-compatible across recipients, they offer a path toward scalable, off-the-shelf cell and tissue therapies that bypass the need for matching or rejection-prone immunosuppressive regimens.
While this technology is still in early development, its long-term promise could help solve one of the most pressing challenges in transplantation: the lack of compatible donors. By building toward this future, we hope to help expand access to safe, timely, and effective treatment options for patients around the world.
Why Universal Donor Cells matter
The success of both cell-based and organ transplantation is often limited by one critical factor: immune compatibility. Whether in advanced therapies or life-saving transplants, patients typically require cells or organs that are immunologically matched — a process that depends on scarce donor availability, individualized preparation, and lifelong immunosuppression.
These limitations result in morbidity and mortality as a consequence of delayed treatments, high costs, and restricted access — particularly in low-resource or time-sensitive settings.
Universal donor cells represent a potential paradigm shift: engineered to be immune-compatible across recipients, they offer a path toward scalable, off-the-shelf cell and tissue therapies that bypass the need for matching or rejection-prone immunosuppressive regimens.
While this technology is still in early development, its long-term promise could help solve one of the most pressing challenges in transplantation: the lack of compatible donors. By building toward this future, we hope to help expand access to safe, timely, and effective treatment options for patients around the world.
Current:
The Status Quo
Future:
The Universal Donor Cell Platfrm
Our Science
Altera is leveraging the unlimited self-renewing capabilities of induced pluripotent stem cells (iPSCs) and advanced gene regulation technologies to build a novel universal donor cell platform.
Our goal is to help overcome one of the greatest challenges in transplantation and advanced therapies: the limited availability of immunologically compatible donors.
By engineering immune-compatible cells that can be used across recipients, we aim to enable scalable, off-the-shelf solutions that expand access to life-changing therapies.
Our Science
Altera is leveraging the unlimited self-renewing capabilities of induced pluripotent stem cells (iPSCs) and advanced gene regulation technologies to build a novel universal donor cell platform.
Our goal is to help overcome one of the greatest challenges in transplantation and advanced therapies: the limited availability of immunologically compatible donors.
By engineering immune-compatible cells that can be used across recipients, we aim to enable scalable, off-the-shelf solutions that expand access to life-changing therapies.
Leadership Team
In The News
About us
Altera Biosciences is a preclinical-stage biotechnology company developing a universal donor cell platform to power the next generation of off-the-shelf allogeneic cell therapies.
Our mission is to remove the barriers of immunogenicity and donor-matching through cell engineering — making cell therapy more scalable, accessible, and impactful across the globe.
We’re driven by a belief that advanced therapies should be designed for everyone — not just a few. That’s why we’re focused on creating foundational technologies that unlock long-term, off-the-shelf solutions for diverse patient populations.
Why Universal Donor Cells matter
The success of both cell-based and organ transplantation is often limited by one critical factor: immune compatibility. Whether in advanced therapies or life-saving transplants, patients typically require cells or organs that are immunologically matched — a process that depends on scarce donor availability, individualized preparation, and lifelong immunosuppression.
These limitations result in morbidity and mortality as a consequence of delayed treatments, high costs, and restricted access — particularly in low-resource or time-sensitive settings.
Universal donor cells represent a potential paradigm shift: engineered to be immune-compatible across recipients, they offer a path toward scalable, off-the-shelf cell and tissue therapies that bypass the need for matching or rejection-prone immunosuppressive regimens.
While this technology is still in early development, its long-term promise could help solve one of the most pressing challenges in transplantation: the lack of compatible donors. By building toward this future, we hope to help expand access to safe, timely, and effective treatment options for patients around the world.
Current:
The Status Quo
Future:
The Universal Donor Cell Platfrm
Our Science
Altera is leveraging the unlimited self-renewing capabilities of induced pluripotent stem cells (iPSCs) and advanced gene regulation technologies to build a novel universal donor cell platform.
Our goal is to help overcome one of the greatest challenges in transplantation and advanced therapies: the limited availability of immunologically compatible donors.
By engineering immune-compatible cells that can be used across recipients, we aim to enable scalable, off-the-shelf solutions that expand access to life-changing therapies.
Our Team
Altera is led by a team of scientists and entrepreneurs with experience spanning cell therapy, gene regulation, and early-stage biotech. Together, we bring a shared commitment to advancing science that’s accessible, globally relevant, and built for real-world impact.
ALEXANDRA MISZEWSKI
Co-Founder & CEO
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
MICHAEL PEPPER, MD, PhD
Co-Founder & Chief Scientific Officer
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
In The News
About us
Why Universal Donor Cells matter
The success of both cell-based and organ transplantation is often limited by one critical factor: immune compatibility. Whether in advanced therapies or life-saving transplants, patients typically require cells or organs that are immunologically matched — a process that depends on scarce donor availability, individualized preparation, and lifelong immunosuppression.
These limitations result in morbidity and mortality as a consequence of delayed treatments, high costs, and restricted access — particularly in low-resource or time-sensitive settings.
Universal donor cells represent a potential paradigm shift: engineered to be immune-compatible across recipients, they offer a path toward scalable, off-the-shelf cell and tissue therapies that bypass the need for matching or rejection-prone immunosuppressive regimens.
While this technology is still in early development, its long-term promise could help solve one of the most pressing challenges in transplantation: the lack of compatible donors. By building toward this future, we hope to help expand access to safe, timely, and effective treatment options for patients around the world.
Current:
The Status Quo
Future:
The Universal Donor Cell Platform
Our Science
Our Team
Altera is led by a team of scientists and entrepreneurs with experience spanning cell therapy, gene regulation, and early-stage biotech. Together, we bring a shared commitment to advancing science that’s accessible, globally relevant, and built for real-world impact.
ALEXANDRA MISZEWSKI
Co-Founder & CEO
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
MICHAEL PEPPER, MD, PhD
Co-Founder & Chief Scientific Officer
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
